Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

ABSTRACT:

Background

Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persistence.

Methods

We conducted a phase 1b-2 multicenter study of obe-cel in adults (≥18 years of age) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The main cohort, cohort 2A, included patients with morphologic disease; patients in cohort 2B had measurable residual disease. The primary end point was overall remission (complete remission or complete remission with incomplete hematologic recovery) in cohort 2A. Secondary end points included event-free survival, overall survival, and safety.

Results

Of the 153 enrolled patients, 127 (83.0%) rece

SUBMITTER: Roddie C 

PROVIDER: S-EPMC12818175 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature